Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM-301 in Glycogen Storage Disease Type Ia
NCT06735755Phase 2Recruiting
- Sponsor
- Beam Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of BEAM-301 in Glycogen storage disease type Ia (GSDIa), sponsored by Beam Therapeutics. Started Dec 2024; status: recruiting.
02
Drugs
BEAM-301
03
Conditions
Glycogen storage disease type Ia (GSDIa)
Beyond the preview
Go deeper on NCT06735755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735755.